Q-omics provides the consensus-scored CH25H profile across patient tissues and cancer cell-line models. CH25H expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, CH25H is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CH25H RNA expression shows 16,960 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight OV, KICH, and LSCC as cancer lineages where CH25H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CH25H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CH25H survival associations across molecular data types. CH25H RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CH25H RNA expression–survival associations across cancer types. High CH25H expression shows unfavorable associations in OV and UVM, but favorable associations in HNSC, LUAD, SKCM and CESC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for CH25H RNA expression.
This table summarizes CH25H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CH25H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CH25H shows lower tumor expression in KICH, BLCA, LUSC, HNSC and UCEC and higher tumor expression in THCA. The KICH box plot shows higher CH25H RNA expression in normal versus tumor tissue (log2 FC = −2.761, t-test p < 0.001).
This table shows molecular features associated with CH25H in patient tissues and cancer cell lines. In patient samples, CH25H shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CH25H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
